Hoyne Christopher, Dreosti Marcus, Shakeshaft John, Baxi Siddartha
Ballarat Austin Radiation Oncology Centre, Ballarat, Victoria, Australia.
Adelaide Radiotherapy Centre, Adelaide, South Australia, Australia.
J Med Radiat Sci. 2017 Jun;64(2):125-130. doi: 10.1002/jmrs.203. Epub 2017 Feb 27.
Recent studies have suggested reducing the dose submandibular glands receive when patients undergo head and neck radiotherapy can play a crucial role in preventing xerostomia. However, they are traditionally not spared due to concern that target coverage may be compromised. We investigated the possibility of sparing the contralateral submandibular gland (cSM) by utilising modern planning techniques.
10 head and neck patients previously treated with conformal therapy at our centre were retrospectively planned using intensity modulated radiation therapy (IMRT), and volumetric modulated arc therapy (VMAT). Each patient was prescribed 70 Gy in 35 fractions to the primary volume, with 56 Gy delivered to the elective nodal areas. The primary objective was to spare the cSM gland using appropriate dose constraints.
Mean dose to the cSM gland was reduced to an acceptable dose level (39 Gy) for all patients replanned using an IMRT or VMAT technique, without compromising planned target volume (PTV) coverage or other critical structures. VMAT was able to reduce the mean dose to 31.5 ± 5.5 Gy compared to 34.5 ± 4.8 Gy of IMRT and offered improved plan conformity.
Sparing the cSM gland is possible using IMRT and VMAT planning, whilst preserving coverage on the elective PTV. This has produced a change in protocol in our department, more focus placed on sparing the SM glands. VMAT is a viable alternative method of delivering treatment and will be utilised when required.
近期研究表明,在患者接受头颈部放疗时降低下颌下腺所接受的剂量,对于预防口干症可能起到关键作用。然而,由于担心靶区覆盖会受到影响,传统上并未对其进行保护。我们研究了利用现代放疗计划技术保护对侧下颌下腺(cSM)的可能性。
对在我们中心先前接受适形放疗的10名头颈部患者进行回顾性研究,采用调强放射治疗(IMRT)和容积调强弧形治疗(VMAT)进行放疗计划。每位患者的原发靶区处方剂量为70 Gy,分35次给予,选择性淋巴结区给予56 Gy。主要目标是通过适当的剂量限制来保护cSM腺。
对于所有采用IMRT或VMAT技术重新规划的患者,cSM腺的平均剂量均降低至可接受水平(39 Gy),且未影响计划靶区(PTV)的覆盖或其他关键结构。与IMRT的34.5±4.8 Gy相比,VMAT能够将平均剂量降低至31.5±5.5 Gy,并提高了计划的适形性。
使用IMRT和VMAT计划可以在保护选择性PTV覆盖的同时保护cSM腺。这导致了我们科室治疗方案的改变,更加注重保护下颌下腺。VMAT是一种可行的替代治疗方法,将在需要时使用。